Kymera Therapeutics, Inc. (KYMR)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 30, 3:32 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow KYMR in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on KYMR and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
KYMR at a glance
Key statistics
$10.47B
Market capitalization
- Previous close
- $122.60
- Open
- $123.71
- Day range
- $117.52 – $125.67
- Volume
- 1.04M
- Average volume (30 sessions)
- 856.7K
- Shares outstanding
- 83.15M
- Earnings per share
- $(4.09)
- Price / book
- 6.5
- Price / sales
- 102.4
- Beta (1 year, vs SPY)
- 0.78
Where the price sits in its year
52-week range
93% of the range
- Below the 52-week high
- -4.0%
- Above the 52-week low
- +124.2%
Completed sessions through Oct 29, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $111.25+10.2%
- 50-day average
- $114.81+6.8%
- 200-day average
- $96.16+27.5%
Between the conventional 30 and 70 bands.
+10.6%
1 week
+9.7%
1 month
+18.6%
3 months
+57.6%
Year to date
+97.9%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with KYMR
KYMR on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on KYMR.
See the plans →
Every planScreen names like KYMR
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on KYMR
Put KYMR on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on KYMR
See whether there is an open premium alert on KYMR, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
KYMR headlines
- Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
GlobeNewswire Inc. · Oct 29, 2026
- Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
GlobeNewswire Inc. · Jun 12, 2026
- Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
GlobeNewswire Inc. · Jun 8, 2026
- Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
GlobeNewswire Inc. · May 15, 2026
- Kymera Therapeutics to Participate in Upcoming May Investor Conferences
GlobeNewswire Inc. · May 6, 2026
- Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
GlobeNewswire Inc. · Apr 23, 2026
- Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
GlobeNewswire Inc. · Jan 13, 2026
- Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Benzinga · Dec 11, 2025
SEC Form 4, most recent first
Insider filings
Mainolfi Nello
−262
Chief Executive Officer, Director · Open-market sale
$30.42K · Oct 1, 2026
Mainolfi Nello
−7.6K
Chief Executive Officer, Director · Open-market sale
$869.78K · Oct 1, 2026
Mainolfi Nello
−5.5K
Chief Executive Officer, Director · Open-market sale
$618.98K · Oct 1, 2026
Mainolfi Nello
−30.0K
Chief Executive Officer, Director · Option exercise
· Oct 1, 2026
Mainolfi Nello
−3.5K
Chief Executive Officer, Director · Open-market sale
$392.83K · Oct 1, 2026
Mainolfi Nello
+30.0K
Chief Executive Officer, Director · Option exercise
$62.40K · Oct 1, 2026
Mainolfi Nello
−8.2K
Chief Executive Officer, Director · Open-market sale
$949.74K · Oct 1, 2026
Mainolfi Nello
−4.9K
Chief Executive Officer, Director · Open-market sale
$552.16K · Oct 1, 2026
About Kymera Therapeutics, Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- Watertown, MA
- Employees
- 285
- Listed since
- Aug 21, 2020
- Website
- kymeratx.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.